U.S. Immunoglobulin MarketU.S. Immunoglobulin Market Decade Long Trends, Analysis and Forecast 2024-2032
U.S. Immunoglobulin Market by Route of Administration (Intravenous, Subcutaneous), by Indication (Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Syndrome, Immune Thrombocytopenic Purpura, Multifocal Motor Neuropathy, Others), by Form (Liquid, Lyophilized), by End-user (Hospitals, Clinics, Homecare), by Forecast 2024-2032
Base Year: 2023
150 Pages
U.S. Immunoglobulin Market Decade Long Trends, Analysis and Forecast 2024-2032
Key Insights
The U.S. Immunoglobulin Market size was valued at USD 8.14 USD Billion in 2023 and is projected to reach USD 14.60 USD Billion by 2032, exhibiting a CAGR of 8.7 % during the forecast period. The US Immunoglobulin Market is the one that is involved with the manufacturing, distribution, and usage of immunoglobulins (Ig), also known as the antibodies, which are the key part of the immunity. The sentence says that either the human plasma or the recombinant technology which are the building blocks of the production of things and the treatments of diseases such as primary and secondary immunodeficiencies, autoimmune diseases, and neurological disorders are the components used for the production of the things and are used for the treatment of the diseases. The antibodies of the body, which are the immunoglobulins, are the main factors that increase the immune system, therefore, they protect the body from harmful substances or pathogens, thus, they give the body passive immunity. The most significant trends in the market these days are the growing number of autoimmune diseases and immunodeficiency disorders, hence, the higher the demand for the Ig therapies. Besides, the new production methods, the product formulas, and the administration procedures are making the therapy more efficient, thus, the patients are gaining advantages from both. Besides, the USA is making big strides in both areas.
U.S. Immunoglobulin Trends
- Rising prevalence of immune disorders and chronic diseases
- Growing demand for personalized medicine
- Technological advancements in immunoglobulin production and delivery systems
Driving Forces: What's Propelling the U.S. Immunoglobulin Market
- Rising Incidence of Immune Disorders and Chronic Diseases: The increasing prevalence of primary immunodeficiencies, secondary immunodeficiencies, Guillain-Barré syndrome (GBS), and chronic inflammatory demyelinating polyneuropathy (CIDP) has significantly expanded the demand for immunoglobulins, driving market growth.
- Personalized Medicine Approach: Immunoglobulins enable personalized treatment strategies for immune disorders, addressing specific patient requirements and optimizing therapeutic outcomes.
- Technological Innovations: Advancements in biotechnology, such as genetic engineering and nanotechnology, have led to the development of innovative immunoglobulin formulations with enhanced efficacy, reduced side effects, and improved delivery mechanisms.
Challenges and Restraints in U.S. Immunoglobulin Market
- High Cost of Treatment: Immunoglobulin therapy can be expensive, which may limit access for some patients.
- Supply Chain Challenges: The COVID-19 pandemic has disrupted the global supply chain for immunoglobulins, leading to potential shortages and price increases.
- Immunogenicity: Some patients may develop antibodies against immunoglobulins, reducing their effectiveness over time.
Emerging Trends in U.S. Immunoglobulin
- Novel Formulations: Pharmaceutical companies are developing new formulations of immunoglobulins to improve patient convenience and compliance.
- Home-Based Administration: Advances in subcutaneous and oral delivery systems are enabling patients to receive immunoglobulin therapy at home.
- Precision Medicine: Ongoing research is focused on identifying biomarkers to tailor immunoglobulin therapy to individual patients.
Growth Catalysts in U.S. Immunoglobulin Industry
- Government Initiatives: Government programs and initiatives aimed at increasing access to immunoglobulins for underserved populations.
- Research and Development: Continued investment in research and development of new and improved immunoglobulin therapies.
- Partnerships and Collaborations: Strategic partnerships between pharmaceutical companies, healthcare providers, and patient advocacy groups to enhance patient care.
Market Segmentation: U.S. Immunoglobulin Analysis
Route of Administration:
- Intravenous
- Subcutaneous
Indication:
- Primary Immunodeficiency
- Secondary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Immune Thrombocytopenic Purpura (ITP)
- Multifocal Motor Neuropathy (MMN)
- Others
Form:
- Liquid
- Lyophilized
End-user:
- Hospitals
- Clinics
- Homecare
Leading Players in the U.S. Immunoglobulin Market
- Takeda Pharmaceutical Company Limited (Japan)
- CSL (U.S.)
- Grifols, S.A. (Spain)
- Octapharma AG (Switzerland)
- Kedrion S.P.A (Italy)
- Pfizer, Inc. (U.S.)
- ADMA Biologics, Inc. (U.S.)
- Bio Products Laboratory Ltd. (U.K.)
Significant developments in U.S. Immunoglobulin Sector
- April 2023: Takeda Pharmaceutical Company Limited received the U.S. FDA approval to expand the use of HYQVIA to treat primary immunodeficiency in children.
- March 2023: The U.S. FDA approved LEQEMBI by Eisai Co., Ltd., and Biogen Inc. under the accelerated approval pathway for treating Alzheimer’s disease.
- March 2022: The United States Patent and Trademark Office granted a new patent (US Patent number: 11,149,079) to BPL for its E+I process. The patent is related to the extraction process of immunoglobulin IgG, an overall increase in the total yield of IgG from blood plasma.
Comprehensive Coverage U.S. Immunoglobulin Market Report
This report provides a comprehensive analysis of the U.S. Immunoglobulin Market, including:
- Market size and growth projections
- Market segmentation and trends
- Competitive landscape and key players
- Industry challenges and opportunities
- Strategic recommendations for market participants
Regional Insight
The U.S. continues to dominate the global immunoglobulin market, accounting for a substantial share due to its large patient population with immune disorders, advanced healthcare infrastructure, and supportive reimbursement policies. The market is expected to maintain its leadership position in the coming years.
DROCT
- D: Drivers: Rising prevalence of immune disorders, technological advancements
- R: Restraints: High cost of treatment, supply chain challenges
- O: Opportunities: Precision medicine, new formulations
- C: Challenges: Immunogenicity, limited access for underserved populations
- T: Trends: Home-based administration, patient-specific treatments
Pricing Analysis
The price of immunoglobulins varies depending on the type, dosage, and administration method. On average, intravenous immunoglobulin (IVIG) costs between USD 1,000 to USD 5,000 per gram.
Import And Export Analysis
The U.S. is a net importer of immunoglobulins. The major import sources are from Europe, China, and India.
Segmentation
The market is segmented by route of administration, indication, form, end-user, and company.
Patent/Trademark Analysis
There is a significant number of patents and trademarks related to immunoglobulins. Key patent holders include Takeda Pharmaceutical Company Limited, CSL, and Grifols, S.A.
U.S. Immunoglobulin Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 8.7% from 2018-2032 |
| Segmentation |
|
Frequently Asked Questions
Table Of Content
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Prevalence of Respiratory Diseases to Drive Market Growth
- 3.3. Market Restrains
- 3.3.1. High Cost Associated with the Treatment to Limit the Market Development
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2018-2030
- 5.1. Market Analysis, Insights and Forecast - by Route of Administration
- 5.1.1. Intravenous
- 5.1.2. Subcutaneous
- 5.2. Market Analysis, Insights and Forecast - by Indication
- 5.2.1. Primary Immunodeficiency
- 5.2.2. Secondary Immunodeficiency
- 5.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
- 5.2.4. Syndrome
- 5.2.5. Immune Thrombocytopenic Purpura
- 5.2.6. Multifocal Motor Neuropathy
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast - by Form
- 5.3.1. Liquid
- 5.3.2. Lyophilized
- 5.4. Market Analysis, Insights and Forecast - by End-user
- 5.4.1. Hospitals
- 5.4.2. Clinics
- 5.4.3. Homecare
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1.
- 5.1. Market Analysis, Insights and Forecast - by Route of Administration
- 6. Northeast U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2018-2030
- 6.1. Market Analysis, Insights and Forecast - By Route of Administration
- 6.1.1 Intravenous
- 6.1.2 and Subcutaneous
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1 Primary Immunodeficiency
- 6.2.2 Secondary Immunodeficiency
- 6.2.3 Chronic Inflammatory Demyelinating Polyneuropathy
- 6.2.4 Syndrome
- 6.2.5 Immune Thrombocytopenic Purpura
- 6.2.6 Multifocal Motor Neuropathy
- 6.2.7 and Others
- 6.3. Market Analysis, Insights and Forecast - By Form
- 6.3.1. Liquid and Lyophilized
- 6.4. Market Analysis, Insights and Forecast - By End-user
- 6.4.1 Hospitals
- 6.4.2 Clinics
- 6.4.3 and Homecare
- 7. Southeast U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2018-2030
- 7.1. Market Analysis, Insights and Forecast - By Route of Administration
- 7.1.1 Intravenous
- 7.1.2 and Subcutaneous
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1 Primary Immunodeficiency
- 7.2.2 Secondary Immunodeficiency
- 7.2.3 Chronic Inflammatory Demyelinating Polyneuropathy
- 7.2.4 Syndrome
- 7.2.5 Immune Thrombocytopenic Purpura
- 7.2.6 Multifocal Motor Neuropathy
- 7.2.7 and Others
- 7.3. Market Analysis, Insights and Forecast - By Form
- 7.3.1. Liquid and Lyophilized
- 7.4. Market Analysis, Insights and Forecast - By End-user
- 7.4.1 Hospitals
- 7.4.2 Clinics
- 7.4.3 and Homecare
- 8. Midwest U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2018-2030
- 8.1. Market Analysis, Insights and Forecast - By Route of Administration
- 8.1.1 Intravenous
- 8.1.2 and Subcutaneous
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1 Primary Immunodeficiency
- 8.2.2 Secondary Immunodeficiency
- 8.2.3 Chronic Inflammatory Demyelinating Polyneuropathy
- 8.2.4 Syndrome
- 8.2.5 Immune Thrombocytopenic Purpura
- 8.2.6 Multifocal Motor Neuropathy
- 8.2.7 and Others
- 8.3. Market Analysis, Insights and Forecast - By Form
- 8.3.1. Liquid and Lyophilized
- 8.4. Market Analysis, Insights and Forecast - By End-user
- 8.4.1 Hospitals
- 8.4.2 Clinics
- 8.4.3 and Homecare
- 9. Southwest U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2018-2030
- 9.1. Market Analysis, Insights and Forecast - By Route of Administration
- 9.1.1 Intravenous
- 9.1.2 and Subcutaneous
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1 Primary Immunodeficiency
- 9.2.2 Secondary Immunodeficiency
- 9.2.3 Chronic Inflammatory Demyelinating Polyneuropathy
- 9.2.4 Syndrome
- 9.2.5 Immune Thrombocytopenic Purpura
- 9.2.6 Multifocal Motor Neuropathy
- 9.2.7 and Others
- 9.3. Market Analysis, Insights and Forecast - By Form
- 9.3.1. Liquid and Lyophilized
- 9.4. Market Analysis, Insights and Forecast - By End-user
- 9.4.1 Hospitals
- 9.4.2 Clinics
- 9.4.3 and Homecare
- 10. West U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2018-2030
- 10.1. Market Analysis, Insights and Forecast - By Route of Administration
- 10.1.1 Intravenous
- 10.1.2 and Subcutaneous
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1 Primary Immunodeficiency
- 10.2.2 Secondary Immunodeficiency
- 10.2.3 Chronic Inflammatory Demyelinating Polyneuropathy
- 10.2.4 Syndrome
- 10.2.5 Immune Thrombocytopenic Purpura
- 10.2.6 Multifocal Motor Neuropathy
- 10.2.7 and Others
- 10.3. Market Analysis, Insights and Forecast - By Form
- 10.3.1. Liquid and Lyophilized
- 10.4. Market Analysis, Insights and Forecast - By End-user
- 10.4.1 Hospitals
- 10.4.2 Clinics
- 10.4.3 and Homecare
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2023
- 11.2. Company Profiles
- 11.2.1 Takeda Pharmaceutical Company Limited (Japan)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 CSL (U.S.)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Grifols S.A. (Spain)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Octapharma AG (Switzerland)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Kedrion S.P.A (Italy)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Pfizer Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 ADMA Biologics Inc. (U.S.)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Bio Products Laboratory Ltd. (U.K.)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 LFB Group (France)
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.1 Takeda Pharmaceutical Company Limited (Japan)
List of Figures
- Figure 1: U.S. Immunoglobulin Market Revenue Breakdown (USD Billion, %) by Product 2023 & 2031
- Figure 2: U.S. Immunoglobulin Market Value Share (%), by Route of Administration 2023 & 2031
- Figure 3: U.S. Immunoglobulin Market Value Share (%), by Indication 2023 & 2031
- Figure 4: U.S. Immunoglobulin Market Value Share (%), by Form 2023 & 2031
- Figure 5: U.S. Immunoglobulin Market Value Share (%), by End-user 2023 & 2031
- Figure 6: U.S. Immunoglobulin Market Share (%) by Company 2023
List of Tables
- Table 1: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 2: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Indication 2018 & 2031
- Table 3: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Form 2018 & 2031
- Table 4: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 5: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 6: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 7: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Indication 2018 & 2031
- Table 8: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Form 2018 & 2031
- Table 9: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 10: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 11: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 12: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Indication 2018 & 2031
- Table 13: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Form 2018 & 2031
- Table 14: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 15: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Country 2018 & 2031
- Table 16: Northeast U.S. Immunoglobulin Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 17: Southeast U.S. Immunoglobulin Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 18: Midwest U.S. Immunoglobulin Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 19: Southwest U.S. Immunoglobulin Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 20: West U.S. Immunoglobulin Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 21: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Route of Administration 2018 & 2031
- Table 22: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Indication 2018 & 2031
- Table 23: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Form 2018 & 2031
- Table 24: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by End-user 2018 & 2031
- Table 25: U.S. Immunoglobulin Market Revenue USD Billion Forecast, by Country 2018 & 2031
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 8.7% from 2018-2032 |
| Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
